Functional tumor cell-intrinsic STING, not host STING, drives local and systemic antitumor immunity and therapy efficacy following cryoablation.
Adaptive Immunity
Immunomodulation
Sarcoma
Translational Medical Research
Tumor Microenvironment
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
accepted:
12
07
2023
medline:
10
8
2023
pubmed:
9
8
2023
entrez:
8
8
2023
Statut:
ppublish
Résumé
Despite its potential utility in delivering direct tumor killing and in situ whole-cell tumor vaccination, tumor cryoablation produces highly variable and unpredictable clinical response, limiting its clinical utility. The mechanism(s) driving cryoablation-induced local antitumor immunity and the associated abscopal effect is not well understood. The aim of this study was to identify and explore a mechanism of action by which cryoablation enhances the therapeutic efficacy in metastatic tumor models. We used the subcutaneous mouse model of the rhabdomyosarcoma (RMS) cell lines RMS 76-9 The results show that cryoablation efficacy is dependent on both adaptive immunity and the STING signaling pathway. Contrary to current literature dictating an essential role of host-derived STING activation as a driver of antitumor immunity in vivo, we show that local tumor control, lung metastasis, and the abscopal effect on distant tumor are all critically dependent on a functioning tumor cell-intrinsic STING signaling pathway, which induces inflammatory chemokine and cytokine responses in the cryoablated TME. This reliance extends beyond cryoablation to include intratumoral STING agonist therapy. Additionally, surveys of gene expression databases and tissue microarrays of clinical tumor samples revealed a wide spectrum of expressions among STING-related signaling components. Tumor cell-intrinsic STING pathway is a critical component underlying the effectiveness of cryoablation and suggests that expression of STING-related signaling components may serve as a potential therapy response biomarker. Our data also highlight an urgent need to further characterize tumor cell-intrinsic STING pathways and the associated downstream inflammatory response evoked by cryoablation and other STING-dependent therapy approaches.
Sections du résumé
BACKGROUND
Despite its potential utility in delivering direct tumor killing and in situ whole-cell tumor vaccination, tumor cryoablation produces highly variable and unpredictable clinical response, limiting its clinical utility. The mechanism(s) driving cryoablation-induced local antitumor immunity and the associated abscopal effect is not well understood.
METHODS
The aim of this study was to identify and explore a mechanism of action by which cryoablation enhances the therapeutic efficacy in metastatic tumor models. We used the subcutaneous mouse model of the rhabdomyosarcoma (RMS) cell lines RMS 76-9
RESULTS
The results show that cryoablation efficacy is dependent on both adaptive immunity and the STING signaling pathway. Contrary to current literature dictating an essential role of host-derived STING activation as a driver of antitumor immunity in vivo, we show that local tumor control, lung metastasis, and the abscopal effect on distant tumor are all critically dependent on a functioning tumor cell-intrinsic STING signaling pathway, which induces inflammatory chemokine and cytokine responses in the cryoablated TME. This reliance extends beyond cryoablation to include intratumoral STING agonist therapy. Additionally, surveys of gene expression databases and tissue microarrays of clinical tumor samples revealed a wide spectrum of expressions among STING-related signaling components.
CONCLUSIONS
Tumor cell-intrinsic STING pathway is a critical component underlying the effectiveness of cryoablation and suggests that expression of STING-related signaling components may serve as a potential therapy response biomarker. Our data also highlight an urgent need to further characterize tumor cell-intrinsic STING pathways and the associated downstream inflammatory response evoked by cryoablation and other STING-dependent therapy approaches.
Identifiants
pubmed: 37553183
pii: jitc-2022-006608
doi: 10.1136/jitc-2022-006608
pmc: PMC10414127
pii:
doi:
Substances chimiques
Cytokines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : F31 CA254259
Pays : United States
Organisme : NIH HHS
ID : S10 OD024981
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA059366
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007250
Pays : United States
Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Proc Natl Acad Sci U S A. 2021 Apr 13;118(15):
pubmed: 33827917
Clin Cancer Res. 2003 Aug 1;9(8):3105-14
pubmed: 12912962
Cancer Immunol Res. 2022 Aug 3;10(8):947-961
pubmed: 35678717
Nature. 2020 Oct;586(7829):363-364
pubmed: 32989308
Cancer Discov. 2019 May;9(5):646-661
pubmed: 30777870
Cell Death Differ. 2021 Mar;28(3):843-860
pubmed: 33214663
Cancer Discov. 2021 May;11(5):1082-1099
pubmed: 33408242
Cancer Cell. 2017 May 8;31(5):711-723.e4
pubmed: 28486109
Nat Commun. 2022 Aug 16;13(1):4822
pubmed: 35973990
Cell Mol Immunol. 2021 Mar;18(3):632-643
pubmed: 33500563
Cell Rep. 2015 May 19;11(7):1018-30
pubmed: 25959818
Immunity. 2018 Oct 16;49(4):754-763.e4
pubmed: 30332631
Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):E4612-E4620
pubmed: 28533362
Nat Commun. 2021 Jul 20;12(1):4405
pubmed: 34285232
Cell Death Differ. 2020 Nov;27(11):2989-3003
pubmed: 32948836
Nature. 2023 Apr;616(7958):806-813
pubmed: 36991128
Cancer. 1988 Jan 15;61(2):209-20
pubmed: 3275486
Nat Rev Immunol. 2021 Sep;21(9):548-569
pubmed: 33833439
Nat Commun. 2019 Jan 9;10(1):100
pubmed: 30626869
Nat Commun. 2021 Nov 4;12(1):6375
pubmed: 34737281
Cancer Res. 2009 Apr 1;69(7):3077-85
pubmed: 19293190
J Vasc Interv Radiol. 2019 Mar;30(3):466-469
pubmed: 30819495
Immunity. 2014 Nov 20;41(5):843-52
pubmed: 25517616
Nature. 2020 Oct;586(7829):429-433
pubmed: 32877915
Med Pediatr Oncol. 1992;20(3):209-14
pubmed: 1574030
Immunity. 2021 Dec 14;54(12):2701-2711
pubmed: 34910940
Nat Rev Clin Oncol. 2020 Jan;17(1):49-64
pubmed: 31595049
Cancer Immunol Immunother. 2023 May;72(5):1327-1335
pubmed: 36394642
J Exp Med. 2019 Apr 1;216(4):867-883
pubmed: 30886058
Cancer Cell. 2022 May 9;40(5):439-440
pubmed: 35487217
Curr Rev Musculoskelet Med. 2015 Dec;8(4):353-60
pubmed: 26508037
Immunity. 2014 Mar 20;40(3):329-41
pubmed: 24560620
Nat Rev Immunol. 2017 Feb;17(2):97-111
pubmed: 27748397
Crit Rev Biomed Eng. 2007;35(1-2):37-121
pubmed: 17956222
Cryobiology. 2014 Feb;68(1):1-11
pubmed: 24239684
J Clin Invest. 2016 Jul 1;126(7):2404-11
pubmed: 27367184
Nature. 2018 Jan 25;553(7689):467-472
pubmed: 29342134
Ann Surg. 1999 May;229(5):602-10; discussion 610-2
pubmed: 10235518
Nature. 2017 Aug 24;548(7668):461-465
pubmed: 28738408
Nature. 2017 Aug 24;548(7668):466-470
pubmed: 28759889
J Vasc Interv Radiol. 2015 Nov;26(11):1652-7.e1
pubmed: 26342882
Int J Hyperthermia. 2019 Nov;36(sup1):10-16
pubmed: 31795837
Cell. 2021 Apr 15;184(8):2033-2052.e21
pubmed: 33765443
N Engl J Med. 1999 Jul 29;341(5):342-52
pubmed: 10423470
Cell Rep. 2019 Oct 29;29(5):1236-1248.e7
pubmed: 31665636
Immunity. 2019 Mar 19;50(3):591-599.e6
pubmed: 30893587
Front Immunol. 2019 Sep 24;10:2283
pubmed: 31608067
Pediatr Blood Cancer. 2011 Dec 1;57(6):921-9
pubmed: 21462302
Nat Genet. 2012 May 29;44(6):619-22
pubmed: 22641210
Cancer. 2008 Nov 1;113(9):2575-96
pubmed: 18837040
Cancer Res. 2015 Sep 1;75(17):3529-42
pubmed: 26330165
Immunity. 2020 Jul 14;53(1):115-126.e5
pubmed: 32640258
Sci Adv. 2021 Oct 08;7(41):eabf6290
pubmed: 34613770
Cancers (Basel). 2022 May 16;14(10):
pubmed: 35626062
BJU Int. 2005 Dec;96(9):1224-9
pubmed: 16287435
Sci Rep. 2022 Jun 30;12(1):10466
pubmed: 35773436
Immunity. 2020 Jan 14;52(1):151-166.e6
pubmed: 31924474
Cancer Cell. 2021 Jan 11;39(1):96-108.e6
pubmed: 33338425
Nat Cell Biol. 2020 Jul;22(7):908
pubmed: 32555433
Mol Cell. 2019 Jul 25;75(2):372-381.e5
pubmed: 31126740
Front Immunol. 2017 Feb 23;8:194
pubmed: 28280496
Immunity. 2014 Nov 20;41(5):830-42
pubmed: 25517615
Nat Immunol. 2016 Sep 20;17(10):1142-9
pubmed: 27648547
Nat Commun. 2017 Sep 5;8(1):427
pubmed: 28874664
Insights Imaging. 2019 May 20;10(1):53
pubmed: 31111237
Nat Chem Biol. 2014 Dec;10(12):1043-8
pubmed: 25344812
Nat Rev Cancer. 2014 Mar;14(3):199-208
pubmed: 24561446
Cancer Res. 2012 Jan 15;72(2):430-9
pubmed: 22108823
Science. 2013 Feb 15;339(6121):826-30
pubmed: 23258412
Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):15408-13
pubmed: 26607445
Nat Commun. 2020 Jul 7;11(1):3382
pubmed: 32636381
Signal Transduct Target Ther. 2022 Jun 20;7(1):196
pubmed: 35725836
Sci Transl Med. 2020 Jun 24;12(549):
pubmed: 32581136
Nat Commun. 2021 Apr 19;12(1):2327
pubmed: 33875663
Cancer Discov. 2019 Jun;9(6):722-737
pubmed: 31015319
J Immunol. 2017 Jul 15;199(2):397-402
pubmed: 28615418
Cancer. 1988 Oct 1;62(7):1257-66
pubmed: 2843274
Cancer Res. 2014 Oct 1;74(19):5409-20
pubmed: 25092895
J Clin Invest. 2019 Jul 25;129(10):4350-4364
pubmed: 31343989
Front Immunol. 2021 Jun 03;12:695150
pubmed: 34149738
Cell. 2020 Jun 25;181(7):1612-1625.e13
pubmed: 32497499
Pharm Pat Anal. 2019 Jul;8(4):87-90
pubmed: 31354104
Immunity. 2018 Sep 18;49(3):490-503.e4
pubmed: 30170810
Science. 2013 Sep 20;341(6152):1390-4
pubmed: 23989956
Cell Mol Gastroenterol Hepatol. 2021;12(1):41-58
pubmed: 33548597
Cell Death Differ. 2018 Mar;25(3):486-541
pubmed: 29362479
J Immunother Cancer. 2022 Sep;10(9):
pubmed: 36126994
Nat Med. 2007 May;13(5):543-51
pubmed: 17479100
Cell Death Differ. 2010 Apr;17(4):616-23
pubmed: 20075940
Proc Natl Acad Sci U S A. 2022 Jul 12;119(28):e2111003119
pubmed: 35787058
Trends Mol Med. 2019 May;25(5):412-427
pubmed: 30885429
Eur J Surg Oncol. 2012 Nov;38(11):1036-42
pubmed: 22947631
J Clin Oncol. 2003 Jul 15;21(14):2719-25
pubmed: 12860950
J Exp Med. 2017 Jun 5;214(6):1769-1785
pubmed: 28484079
Cancer. 1993 Mar 1;71(5):1904-22
pubmed: 8448756
J Vasc Interv Radiol. 2010 Aug;21(8 Suppl):S187-91
pubmed: 20656228
Nat Methods. 2013 May;10(5):407-9
pubmed: 23524392